Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review

Shamasunder H Acharya, Alison Avenell, Sam Philip, Jennifer Burr, John S Bevan, Prakash Abraham

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

An association between radioiodine therapy (RAI) for Graves' disease (GD) and the development or worsening of Graves' ophthalmopathy (GO) is widely quoted but there has been no systematic review of the evidence.

We undertook a systematic review of randomized controlled trials (RCTs) to assess whether RAI for GD is associated with increased risk of ophthalmopathy compared with antithyroid drugs (ATDs) or surgery. We also assessed the efficacy of glucocorticoid prophylaxis in the prevention of occurrence or progression of ophthalmopathy, when used with RAI.

We identified RCTs regardless of language or publication status by searching six databases and trial registries. Dual, blinded data abstraction and quality assessment were undertaken. Random effects meta-analyses were used to combine the study data. Ten RCTs involving 1136 patients permitted 13 comparisons. Two RCTs compared RAI with ATD. Two RCTs compared RAI with thyroidectomy. Four RCTs compared the use of adjunctive ATD with RAI vs. RAI. Five RCTs examined the use of glucocorticoid prophylaxis with RAI.

RAI was associated with an increased risk of ophthalmopathy compared with ATD [relative risk (RR) 4.23; 95% confidence interval (CI): 2.04-8.77] but compared with thyroidectomy, there was no statistically significant increased risk (RR 1.59, 95% CI 0.89-2.81). The risk of severe GO was also increased with RAI compared with ATD (RR 4.35; 95% CI 1.28-14.73). Prednisolone prophylaxis for RAI was highly effective in preventing the progression of GO in patients with pre-existing GO (RR 0.03; 95% CI 0.00-0.24). The use of adjunctive ATD with RAI was not associated with any significant benefit on the course of GO.

RAI for GD is associated with a small but definite increased risk of development or worsening of Graves' ophthalmopathy compared with ATDs. Steroid prophylaxis is beneficial for patients with pre-existing GO.

Original languageEnglish
Pages (from-to)943-950
Number of pages8
JournalClinical Endocrinology
Volume69
Issue number6
Early online date21 Apr 2008
DOIs
Publication statusPublished - Dec 2008

Keywords

  • Antithyroid Agents
  • Graves Disease
  • Graves Ophthalmopathy
  • Humans
  • Iodine Radioisotopes
  • Prednisolone
  • Randomized Controlled Trials as Topic
  • Risk
  • Thyroidectomy

Cite this

Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy : a systematic review. / Acharya, Shamasunder H; Avenell, Alison; Philip, Sam; Burr, Jennifer; Bevan, John S; Abraham, Prakash.

In: Clinical Endocrinology, Vol. 69, No. 6, 12.2008, p. 943-950.

Research output: Contribution to journalArticle

@article{07a644d62cb541d9b604744e7e1237f5,
title = "Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review",
abstract = "An association between radioiodine therapy (RAI) for Graves' disease (GD) and the development or worsening of Graves' ophthalmopathy (GO) is widely quoted but there has been no systematic review of the evidence.We undertook a systematic review of randomized controlled trials (RCTs) to assess whether RAI for GD is associated with increased risk of ophthalmopathy compared with antithyroid drugs (ATDs) or surgery. We also assessed the efficacy of glucocorticoid prophylaxis in the prevention of occurrence or progression of ophthalmopathy, when used with RAI.We identified RCTs regardless of language or publication status by searching six databases and trial registries. Dual, blinded data abstraction and quality assessment were undertaken. Random effects meta-analyses were used to combine the study data. Ten RCTs involving 1136 patients permitted 13 comparisons. Two RCTs compared RAI with ATD. Two RCTs compared RAI with thyroidectomy. Four RCTs compared the use of adjunctive ATD with RAI vs. RAI. Five RCTs examined the use of glucocorticoid prophylaxis with RAI.RAI was associated with an increased risk of ophthalmopathy compared with ATD [relative risk (RR) 4.23; 95{\%} confidence interval (CI): 2.04-8.77] but compared with thyroidectomy, there was no statistically significant increased risk (RR 1.59, 95{\%} CI 0.89-2.81). The risk of severe GO was also increased with RAI compared with ATD (RR 4.35; 95{\%} CI 1.28-14.73). Prednisolone prophylaxis for RAI was highly effective in preventing the progression of GO in patients with pre-existing GO (RR 0.03; 95{\%} CI 0.00-0.24). The use of adjunctive ATD with RAI was not associated with any significant benefit on the course of GO.RAI for GD is associated with a small but definite increased risk of development or worsening of Graves' ophthalmopathy compared with ATDs. Steroid prophylaxis is beneficial for patients with pre-existing GO.",
keywords = "Antithyroid Agents, Graves Disease, Graves Ophthalmopathy, Humans, Iodine Radioisotopes, Prednisolone, Randomized Controlled Trials as Topic, Risk, Thyroidectomy",
author = "Acharya, {Shamasunder H} and Alison Avenell and Sam Philip and Jennifer Burr and Bevan, {John S} and Prakash Abraham",
year = "2008",
month = "12",
doi = "10.1111/j.1365-2265.2008.03279.x",
language = "English",
volume = "69",
pages = "943--950",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy

T2 - a systematic review

AU - Acharya, Shamasunder H

AU - Avenell, Alison

AU - Philip, Sam

AU - Burr, Jennifer

AU - Bevan, John S

AU - Abraham, Prakash

PY - 2008/12

Y1 - 2008/12

N2 - An association between radioiodine therapy (RAI) for Graves' disease (GD) and the development or worsening of Graves' ophthalmopathy (GO) is widely quoted but there has been no systematic review of the evidence.We undertook a systematic review of randomized controlled trials (RCTs) to assess whether RAI for GD is associated with increased risk of ophthalmopathy compared with antithyroid drugs (ATDs) or surgery. We also assessed the efficacy of glucocorticoid prophylaxis in the prevention of occurrence or progression of ophthalmopathy, when used with RAI.We identified RCTs regardless of language or publication status by searching six databases and trial registries. Dual, blinded data abstraction and quality assessment were undertaken. Random effects meta-analyses were used to combine the study data. Ten RCTs involving 1136 patients permitted 13 comparisons. Two RCTs compared RAI with ATD. Two RCTs compared RAI with thyroidectomy. Four RCTs compared the use of adjunctive ATD with RAI vs. RAI. Five RCTs examined the use of glucocorticoid prophylaxis with RAI.RAI was associated with an increased risk of ophthalmopathy compared with ATD [relative risk (RR) 4.23; 95% confidence interval (CI): 2.04-8.77] but compared with thyroidectomy, there was no statistically significant increased risk (RR 1.59, 95% CI 0.89-2.81). The risk of severe GO was also increased with RAI compared with ATD (RR 4.35; 95% CI 1.28-14.73). Prednisolone prophylaxis for RAI was highly effective in preventing the progression of GO in patients with pre-existing GO (RR 0.03; 95% CI 0.00-0.24). The use of adjunctive ATD with RAI was not associated with any significant benefit on the course of GO.RAI for GD is associated with a small but definite increased risk of development or worsening of Graves' ophthalmopathy compared with ATDs. Steroid prophylaxis is beneficial for patients with pre-existing GO.

AB - An association between radioiodine therapy (RAI) for Graves' disease (GD) and the development or worsening of Graves' ophthalmopathy (GO) is widely quoted but there has been no systematic review of the evidence.We undertook a systematic review of randomized controlled trials (RCTs) to assess whether RAI for GD is associated with increased risk of ophthalmopathy compared with antithyroid drugs (ATDs) or surgery. We also assessed the efficacy of glucocorticoid prophylaxis in the prevention of occurrence or progression of ophthalmopathy, when used with RAI.We identified RCTs regardless of language or publication status by searching six databases and trial registries. Dual, blinded data abstraction and quality assessment were undertaken. Random effects meta-analyses were used to combine the study data. Ten RCTs involving 1136 patients permitted 13 comparisons. Two RCTs compared RAI with ATD. Two RCTs compared RAI with thyroidectomy. Four RCTs compared the use of adjunctive ATD with RAI vs. RAI. Five RCTs examined the use of glucocorticoid prophylaxis with RAI.RAI was associated with an increased risk of ophthalmopathy compared with ATD [relative risk (RR) 4.23; 95% confidence interval (CI): 2.04-8.77] but compared with thyroidectomy, there was no statistically significant increased risk (RR 1.59, 95% CI 0.89-2.81). The risk of severe GO was also increased with RAI compared with ATD (RR 4.35; 95% CI 1.28-14.73). Prednisolone prophylaxis for RAI was highly effective in preventing the progression of GO in patients with pre-existing GO (RR 0.03; 95% CI 0.00-0.24). The use of adjunctive ATD with RAI was not associated with any significant benefit on the course of GO.RAI for GD is associated with a small but definite increased risk of development or worsening of Graves' ophthalmopathy compared with ATDs. Steroid prophylaxis is beneficial for patients with pre-existing GO.

KW - Antithyroid Agents

KW - Graves Disease

KW - Graves Ophthalmopathy

KW - Humans

KW - Iodine Radioisotopes

KW - Prednisolone

KW - Randomized Controlled Trials as Topic

KW - Risk

KW - Thyroidectomy

U2 - 10.1111/j.1365-2265.2008.03279.x

DO - 10.1111/j.1365-2265.2008.03279.x

M3 - Article

C2 - 18429949

VL - 69

SP - 943

EP - 950

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 6

ER -